Search PubMed⌕ Search

Biomedical subjects

C Chiba

Publications and source records attributed to C Chiba.

33 records · Page 2Linked to original sources
PubMed1983

Benign familial neonatal convulsions.

A pedigree of so-called benign familial neonatal convulsions was reported. Nine members experienced convulsions in the neonatal period and/or in early infancy. All members except one had good prognosis. One member had mild mental retardation and epilepsy with rolandic EEG foci. It was suggested that some common genetic factors may be involved in the etiology of benign familial neonatal convulsions, convulsions of unknown etiology in infancy (Fukuyama) and epilepsy with rolandic EEG foci. A review of literature revealed that about 14% of cases with benign familial neonatal convulsions eventually developed epilepsy.

Adolescent↗
PubMed1983

[Experimental and clinical evaluation of cefotetan in pediatrics].

Basic and clinical studies on cefotetan (CTT) were carried out and the results were as follows: Absorption and excretion Two patients were given 10 mg/kg of CTT by one shot intravenous injection. At 30 minutes after injection, mean serum level was 76.5 micrograms/ml and the half-life time was 2.3 hours. Mean 6-hour urinary recovery in same patients was 57.5%. Clinical evaluation Forty-two patients were treated with CTT, in doses of 19.2-102.9 mg/kg divided 2-4 times per day for 3-10 days intravenously. Responses were excellent in 14, good in 23, fair in 1, poor in 4, and the overall efficacy rate was 88.1%. As to adverse reaction, urticaria was observed in 1 patient. Abnormal laboratory data noted were elevation of GOT in 1, GOT and GPT in 2, creatinine in 1, and eosinophilia in 3 patients.

Adolescent↗
PubMed1983

[Clinical evaluation of cefpiramide in pediatrics].

Cefpiramide (CPM) is a newly developed cephalosporin. Clinical studies on this drug were carried out and the results were as follows; Forty-three patients (purulent lymphadenitis 2, cellulitis 2, purulent otitis media 1, purulent tonsillitis 3, acute bronchitis 2, pneumonia 22, bronchiectasis 1, urinary tract infection 10) were treated with CPM, in doses of 20 approximately 82 mg/kg divided 2 approximately 4 times per day for 3 approximately 11 days intravenously. The overall efficacy rate was 83.7%. As to adverse reaction, 4 cases, which includes 3 cases of diarrhea and 1 case of exanthema, were observed. Abnormal laboratory data noted were liver dysfunction in 3 cases (6.8%), and eosinophilia in 2 cases (4.5%).

Adolescent↗
PubMed1982

[Basic and clinical studies on cefmenoxime in pediatric field].

Cefmenoxime (CMX) is a newly developed cephalosporin. Basic and clinical studies on this drug was carried out and the results were as follows. 1. Serum level and urinary recovery A 7 years old male was administered 10 mg per kilogram of CMX by one shot intravenous injection. Serum levels were 23.3 micrograms/ml at the time of 15 minutes after injection, 12.0 micrograms/ml at 30 minutes, 3.9 micrograms/ml at 1 hour, 2.0 micrograms/ml at 2 hours, and 0.3 micrograms/ml at 4 hours. In this same patient, 6-hour urinary recovery was 54.7%. 2. Clinical evaluation and adverse reaction Thirty-seven patients (upper respiratory infection 4, pneumonia 20, pyothorax 1, purulent lymphadenitis 1, cellulitis 2, sepsis 1 and urinary tract infection 8) were treated with CMX in doses of 30 approximately 212 mg/kg divided 3 approximately 4 times per day for 1.5 approximately 21 days intravenously. The overall efficacy rate was 94.6%. As to adverse reaction, exanthema and drug fever were observed in 1 patient respectively. Abnormal laboratory data noted were eosinophilia in 2.3%, and elevation of serum transaminase in 9.8%.

Cefmenoxime↗